News & media

Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed as new Chairman of the Board. Incumbent Chairman Mauro Ajani to continue as a Board member. Additional Board changes proposed for the upcoming AGM.   Dublin, Ireland – 25 April 2024: Cosmo Pharmaceuticals N.V. (SIX: […]

Dublin, Ireland – 12 April 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy […]

  Medtronic deal accounted in 2024, to inject USD 200m cash. FDA approval of GI Genius new enhanced operating system. New GI drug development program announced. Outlook for 2025.   Dublin, Ireland – 20 March 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023. […]

Dublin, Ireland – 19 March 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for […]

Dublin, Ireland – 25 January 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET.   FY 2023 Results Webcast   Cosmo invites investors, financial analysts and business/life sciences journalists to a live video webcast presentation which […]

Agreement expands partnership between Cosmo Pharmaceuticals and Medtronic, set to transform endoscopy with cutting-edge AI technology   Dublin, Ireland – 11 December 2023: Cosmo Pharmaceuticals (SIX:COPN, XETRA:C43) (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in […]

Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash. About Cosmo Cosmo is a pharmaceutical company focused on developing and commercializing products to treat selected gastrointestinal disorders, to […]

Dublin, Ireland – 10 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”), a leading pharmaceutical company dedicated to enhancing the lives of individuals suffering from acne, is delighted to announce a pivotal step forward in its mission. Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) […]

Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the signing of a license agreement for Winlevi® (clascoterone) cream 1% in the Middle East and North Africa (MENA) region (Kingdom of Saudi Arabia, Jordan, Egypt, Morocco, Algeria, […]

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland and Mumbai, India – September 27, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (“Glenmark”), today announced the signing of distribution and license agreements for Winlevi® (clascoterone cream 1%) in Europe and South Africa. Under the […]